



an Open Access Journal by MDPI

Anticancer Prodrug

Guest Editor:

Prof. Dr. William L. Stone

Department of Pediatrics, James
H. Quillen College of Medicine,
East Tennessee State University,
Johnson City, TN 37614, USA

Deadline for manuscript
submissions:

closed (30 April 2019)

Message from the Guest Editor

Dear Colleagues,

I would like to invite you to contribute an article to upcoming special issue of *Pharmaceutics* focusing on the development and clinical potential of anticancer prodrugs. The general scope of this special issue is outlined below. Anticancer prodrugs can broadly be defined as nontoxic agents selectively activated to chemotherapeutic drugs in cancer cells, tumors or the tumor microenvironment. Anticancer prodrugs can also serve as adjuvants to enhance or beneficially affect another cancer therapy, e.g., radiation therapy. As a branch of precision oncology, the clinical application of anticancer prodrugs holds the promise of individualized treatment with the maximum therapeutic response with minimum side-effects. The application of “omics” technologies, such as genomics and proteomics, to characterize tumors is rapidly advancing the discovery of novel cancer biomarkers.

Guest Editor: Prof. William L. Stone

Keywords

- anticancer
- prodrugs
- chemotherapy
- personalized medicine
- tumors
- oxidative stress
- hypoxia
- proteomics
- genomics



mdpi.com/si/21202

Special Issue



pharm

Indexed in:
PubMed

CITESCORE
7.9

IMPACT
FACTOR
4.9

an Open Access
Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPlus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[X@MDPIpharma](#)